Detalhe da pesquisa
1.
Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).
Mod Rheumatol
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491996
2.
Preliminary gait analysis of frail versus older adults.
J Phys Ther Sci
; 36(2): 87-93, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38304149
3.
Management of chronic rheumatic diseases in women 18-45 years of age in Asia Pacific: insights from patient and clinician surveys.
Rheumatol Int
; 43(4): 721-733, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36163594
4.
Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).
J Orthop Sci
; 2023 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37076376
5.
Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
Mod Rheumatol
; 33(1): 96-103, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35234889
6.
Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study.
Mod Rheumatol
; 33(5): 891-898, 2023 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35975317
7.
Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Mod Rheumatol
; 33(2): 292-301, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289372
8.
Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors.
Mod Rheumatol
; 31(1): 80-87, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32148143
9.
Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study.
Mod Rheumatol
; 31(4): 796-802, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33492191
10.
Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept.
Clin Exp Rheumatol
; 38(5): 933-939, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32083543
11.
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study.
Mod Rheumatol
; 30(3): 434-441, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31390271
12.
Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system.
Mod Rheumatol
; 29(6): 910-918, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30220237
13.
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Mod Rheumatol
; 28(1): 119-125, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28463029
14.
Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Mod Rheumatol
; 28(2): 221-226, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28701065
15.
Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Mod Rheumatol
; 26(2): 169-74, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26140467
16.
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Rheumatology (Oxford)
; 54(1): 113-20, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25102861
17.
Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
Rheumatology (Oxford)
; 54(5): 854-9, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25339638
18.
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Rheumatol Int
; 35(10): 1707-16, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25991396
19.
Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Mod Rheumatol
; 25(2): 251-6, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25211402
20.
Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry.
Mod Rheumatol
; 25(6): 825-30, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25775147